Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for Reblozyl® Supplemental Biologics License Application Pharmaceutical Investing
AUPH INVESTOR NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses Exceeding $100K to Inquire About Securities Class Action Investigation - AUPH Pharmaceutical Investing
Long Term Holders of Abbott Laboratories Contact Johnson Fistel for Information Regarding Investigation Pharmaceutical Investing
Abbott's FreeStyle® Libre is First and Only CGM System to Gain Expanded Reimbursement in Japan to Include All People with Diabetes Who Use Insulin Pharmaceutical Investing
Knight Therapeutics Reports Fourth Quarter and Year-End 2021 Results and Provides 2022 Revenue Guidance Pharmaceutical Investing
Universal Ibogaine to Participate in the 2022 Virtual Growth Conference - Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT Pharmaceutical Investing
New Data on Cost Impact of Treating Opioid-Induced Constipation with FDA-Approved Medications, Including Salix's RELISTOR® Subcutaneous Injection , in The Emergency Department Is Published in Advances In Therapy Pharmaceutical Investing
Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults Life Science Investing
AUPH Equity Alert: ROSEN, Top Ranked Investor Counsel, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation - AUPH Pharmaceutical Investing
Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer Life Science Investing
UNIVERSAL IBOGAINE EXPANDS RESEARCH TEAM WITH JULIE DUMOUCHEL, DIRECTOR OF CLINICAL TRIALS Pharmaceutical Investing
